Navigation Links
A*STAR and Institut Merieux/bioMerieux invest S$3m ($2.2m) in tuberculosis research
Date:8/12/2010

An investment of S$3 million is being pumped into tuberculosis (TB) research by A*STAR's Singapore Immunology Network (SIgN), bioindustrial group Institut Mrieux and its in vitro diagnostics company bioMrieux. The project, which involves setting up a joint laboratory in Biopolis, Singapore aims to investigate and identify novel biomarkers that could allow early identification of individuals at risk of TB disease development and disease reactivation. This could lead to better diagnosis and treatment for the highly contagious disease.

At the shared lab, researchers from SIgN and bioMrieux will study the immune cells in the blood of infected individuals without active TB, and compare them with those in individuals with active TB, as well as non-infected healthy controls. Any change in gene expression and behaviour of the immune cells will then be analysed to identify biomarkers associated with TB infection and/or TB re-activation. This information would be especially pertinent to clinicians and researchers as current tests cannot reliably detect if the individual is at risk of developing the disease. In addition, the identification of predictive biomarkers will also help clinicians accurately assess patients' responses to TB treatment and deal appropriately with those who have developed drug resistance to Mycobacterium tuberculosis, the bacterium responsible for causing TB. This will lead to early and accurate assessment of the effectiveness of treatment in TB patients.

One of the lead researchers involved in the collaboration is Prof Paola Castagnoli, Scientific Director of SIgN. Said Prof Castagnoli, "The risk of developing active TB is higher in persons with weak immune systems, especially in those infected with HIV, and young children under the age of five. There is an urgent need to understand and find new ways to eradicate the disease through prediction, early detection and effective treatment and this timely collaboration seeks to accomplish exactly that." Prof Castagnoli was part of a team of scientists that published findings on the way dendritic cells and macrophages cope with Mycobacterium tuberculosis in 2008.

The co-investigator on the project, Professor Christian Brechot, who is also the Vice President of Institut Mrieux in charge of scientific and medical affairs, said, "We are very pleased with this partnership between Institut Merieux, bioMrieux and SIgN. It reflects the strategy of Institut Mrieux and its companies to establish long-term partnerships with internationally recognised research institutions, in particular in Singapore. The joint laboratory will focus its activities on tuberculosis, as part of Institut Mrieux's research programs, as well as on oncology. We look forward to the success of this important agreement."

Prof Philippe Kourilsky, Chairman of SIgN, said, "Infectious disease is an area that cannot be tackled alone Singapore has identified infectious diseases as one of its flagship areas of focus for its research efforts and is working closely with its regional and global partners; SIgN already has some meaningful partnerships with several industry players including Cytos and Vivalis. We are excited at this opportunity to partner Institut Mrieux and bioMrieux, which we hope will accelerate the process of discovery and find something of direct impact to the treatment and management of tuberculosis. This collaboration will reinforce SIgN's position as a premier immunology research centre that focuses on addressing the pressing diseases facing Singapore and the region."


'/>"/>

Contact: Yunshi Wang
wang_yunshi@a-star.edu.sg
656-826-6443
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related medicine news :

1. A*STAR scientist receives international award for innovation in healthcare technology
2. Help wanted: Highly cited researchers needed for high-ranking positions at research institutions
3. UT Southwesterns cancer center earns National Cancer Institute designation
4. OHSU Knight Cancer Institute researchers isolate importance of gene in breast cancer prognosis
5. Kennedy Krieger Institutes Dr. Paul Lipkin selected for national health policy fellowship
6. VCU first Virginia institution to join national network of academic research centers
7. DTM Systems Is Pleased To Announce That Aaron Alsop Has Achieved The Project Management Professional Credential With The Project Management Institute
8. News from Karolinska Institutet at ESOF 2010
9. Advanced Pain Institute Opens Expanded Los Angeles Area Pain Management Center
10. Cambridge Healthtech Institute Announces its Second Annual "The Bioprocessing Summit"
11. Aspirus Heart & Vascular Institute Surgeon First in State to Implant Heart Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved ... procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive list ...
(Date:3/28/2017)... ... 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of all ... lot to offer to the discussion of dealing with excess skin oil. “Oily skin is ... home remedies that can help remove the oily shine while keeping the skin fresh and ...
(Date:3/27/2017)... Aurora, CO (PRWEB) , ... March 27, 2017 , ... ... Dr. Mark Braasch for leading sleep apnea treatment, with or without a referral. Sleep ... the condition, which can include daytime sleepiness, morning headaches and chronic snoring. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
(Date:3/27/2017)... 27, 2017 Summary This ... Eli Lilly and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced ... efficacy studies. The company is harnessing the power of ... A, in an effort to find a better treatment ... 4 weeks of treatment in transgenic mice, the lead ... a full toxicology report of various organs. Cytotoxic T-cells ...
Breaking Medicine Technology: